N-3-[5-(2-methyl-6-[(3-morpholinopropyl)amino]-4-pyrimidinylamino)-1H-3-pyrazolyl]phenyl-1-benzenesulfonamide | 1327167-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-3-[5-(2-methyl-6-[(3-morpholinopropyl)amino]-4-pyrimidinylamino)-1H-3-pyrazolyl]phenyl-1-benzenesulfonamide
• 英文别名: N-3-[5-(2-methyl-6-[(3-morpholinopropyl)amino]-4-pyrimidinylamino)-1H-pyrazol-3-yl]phenyl-1-benzenesulfonamide；N-[3-[3-[[2-methyl-6-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]amino]-1H-pyrazol-5-yl]phenyl]benzenesulfonamide
• CAS: 1327167-13-4
• 化学式: C₂₇H₃₂N₈O₃S
• 分子量: 548.669
• InChiKey: FMECAVUOMUCKKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  146
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 在 吡啶 、 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 15.0h， 生成 N-3-[5-(2-methyl-6-[(3-morpholinopropyl)amino]-4-pyrimidinylamino)-1H-3-pyrazolyl]phenyl-1-benzenesulfonamide
  参考文献：
  名称：

  Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)

  摘要：

  Preclinical investigations and early clinical trial studies suggest that FLT3 inhibitors offer a viable therapy for acute myeloid leukemia. However, early clinical data for direct FLT3 inhibitors provided only modest results because of the failure to fully inhibit FLT3. We have designed and synthesized a novel class of 3-phenyl-1H-5-pyrazolylamine-derived compounds as FLT3 inhibitors which exhibit potent FLT3 inhibition and high selectivity toward different receptor tyrosine kinases. The structure-activity relationships led to the discovery of two series of FLT3 inhibitors, and some potent compounds within these two series exhibited comparable potency to FLT3 inhibitors sorafenib (3) and ABT-869 (4) in both wt-FLT3 enzyme inhibition and FLT3-ITD inhibition on cell growth (MOLM-13 and MV4; 11 cells). In particular, the selected compound 12a exhibited the ability to regress tumors in mouse xenograft models using MOLM-13 and MV4; 11 cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.016

文献信息

• PYRAZOLE COMPOUNDS AND THIAZOLE COMPOUNDS AS PROTEIN KINASES INHIBITORS
  申请人：Jiaang Weir-Torn

  公开号：US20120225880A1

  公开（公告）日：2012-09-06

  A compound of formula (I): wherein A, B, D, X, Y, R 1 , R 2 , R 3 , m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.

  其中A、B、D、X、Y、R1、R2、R3、m、p和q的化合物的化学式（I）： 还公开了一种抑制FMS样酪氨酸激酶3、极光激酶或血管内皮生长因子受体的方法。
• US9255072B2
  申请人：——

  公开号：US9255072B2

  公开（公告）日：2016-02-09
• Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
  作者：Wen-Hsing Lin、Shu-Yi Hsieh、Shih-Chieh Yen、Chiung-Tong Chen、Teng-Kuang Yeh、Tsu Hsu、Cheng-Tai Lu、Ching-Ping Chen、Chun-Wha Chen、Ling-Hui Chou、Yu-Lin Huang、An-Huei Cheng、Yun-I Chang、Ya-Ju Tseng、Kuei-Rong Yen、Yu-Sheng Chao、John T.-A. Hsu、Weir-Torn Jiaang

  DOI：10.1016/j.bmc.2011.06.016

  日期：2011.7

  Preclinical investigations and early clinical trial studies suggest that FLT3 inhibitors offer a viable therapy for acute myeloid leukemia. However, early clinical data for direct FLT3 inhibitors provided only modest results because of the failure to fully inhibit FLT3. We have designed and synthesized a novel class of 3-phenyl-1H-5-pyrazolylamine-derived compounds as FLT3 inhibitors which exhibit potent FLT3 inhibition and high selectivity toward different receptor tyrosine kinases. The structure-activity relationships led to the discovery of two series of FLT3 inhibitors, and some potent compounds within these two series exhibited comparable potency to FLT3 inhibitors sorafenib (3) and ABT-869 (4) in both wt-FLT3 enzyme inhibition and FLT3-ITD inhibition on cell growth (MOLM-13 and MV4; 11 cells). In particular, the selected compound 12a exhibited the ability to regress tumors in mouse xenograft models using MOLM-13 and MV4; 11 cells. (C) 2011 Elsevier Ltd. All rights reserved.